A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)

NCT01900106 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

HIV Infection

Interventions

DRUG: abacavir/lamivudine + raltegravir
DRUG: abacavir/lamivudine + darunavir/ritonavir

Sponsor

University of Modena and Reggio Emilia